A phas Ib trial of CEP 9722 in patients with solid tumours
Latest Information Update: 20 Mar 2017
At a glance
- Drugs CEP 9722 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Mar 2017 New trial record
- 16 Mar 2017 According to a Fortress Biotech media release, this trial is planned to commence in the next 12 months.